Top

CardioVascular and Interventional Radiology

Published in:

01-09-2008 | Laboratory Investigation

Transarterial Chemoembolization Using Cisplatin Powder in a Rabbit Model of Liver Cancer

Authors: Kengo Morimoto, Hiroshi Sakaguchi, Toshihiro Tanaka, Kiyosei Yamamoto, Hiroshi Anai, Takayuki Hayashi, Mitsuo Satake, Kimihiko Kichikawa

Published in: CardioVascular and Interventional Radiology | Issue 5/2008

Abstract

The purpose of this study was to investigate the pharmacological advantages of transarterial chemoembolization (TACE) with cisplatin powder for hypervascular hepatic tumors in animal experiments. VX2 tumors were transplanted to the livers of nine rabbits. Cisplatin (1 mg/kg) was infused into the proper hepatic artery. In the cisplatin-HAI group, cisplatin solution was infused. In the cisplatin-GS-TACE group, after infusion of cisplatin solution, gelatin sponge particles were used for embolization. In the cisplatin-Lp-TACE group, after infusion of a cisplatin powder and lipiodol (10 mg/ml) suspension, gelatin sponge particles were used for embolization. Before and after administration, platinum concentrations in plasma were measured. Using liver specimens that were excised 60 min after infusion, platinum concentrations in tumorous and nontumorous liver tissues were measured. The mean platinum concentration in tumorous tissue was 0.88 μg/ml for the cisplatin-HAI group, 1.23 μg/ml for the cisplatin-GS-TACE group, and 12.65 μg/ml for the cisplatin-Lp-TACE group. The platinum concentration for the cisplatin-Lp-TACE group was significantly higher than that for the cisplatin-HAI group (p = 0.004) and the cisplatin-GS-TAE group (p = 0.004). The mean platinum concentration in nontumorous liver tissue was 0.98 μg/ml for the cisplatin-HAI group, 1.13 μg/ml for the cisplatin-GS-TACE group, and 1.09 μg/ml for the cisplatin-Lp-TACE group; no significant differences were seen. At both 5 and 10 min after infusion, the platinum concentrations for the cisplatin-Lp-TACE group were lower than those for the other two groups. The present results suggest that TACE using cisplatin powder/lipiodol suspension and gelatin sponge for hypervascular hepatic tumors has a number of pharmacological advantages.

Lo CN, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171PubMedCrossRef

Llovet JM, Real MI, Montana X et al (2002) Arterial embolizasion or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellur carcinoma: a randomized controlled trial. Lancet 359:1734–1739PubMedCrossRef

Ohishi H, Yoshimura H, Uchida H et al (1989) Transcatheter arterial embolization using iodozed oil (lipiodol) mixed with an anticancer drug for the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 23:S33–S36PubMedCrossRef

Uchida H, Ohishi H, Matsuo N et al (1990) Transcatheter hepatic segmental arterial embolization using lipiodol mixed with an anticancer drug and gelfoam particles for hepatocellur carcinoma. CardioVasc Interv Radiol 13:140–145CrossRef

Nakamura I, Hashimoto T, Oi H et al (1989) Transcatheter oily chemoembolization of hepatocelluar carcinoma. Radiology 170:783–786PubMed

Takayasu K, Shima Y, Muramatsu et al (1987) Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 162:345–351

Lai CL, Wu PC, Chan CG et al (1988) Doxorubicin versus no antitumor thrapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62:479–483PubMedCrossRef

Bokemeyer C, Kynast B, Harstrick A et al (1995) No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 35:334–338PubMedCrossRef

Nagasue N, Yukawa H, Okamura J et al (1986) Intraarterial administration of epirubicin in the treatment of non-resectable hepatocellular carcinoma. Epirubicin Study Group for Hepatocellular. Jpn J Cancer Chemother 13:2786–2792

10.

Einhorn LH, Williams SD (1979) The role of cis-platinum in solid-tumor therapy. N Engl J Med 300:289–291PubMed

11.

Okada S, Okazaki N, Nose H et al (1993) A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 50:22–26PubMedCrossRef

12.

Abe R, Akiyoshi T, Koba F et al (1988) ‘Two-route chemotherapy’ using intra-arterial cisplatin and intravenous sodium thiosulfate, its neutralizing agent, for hepatic malignancies. Eur J Cancer Clin Oncol 24:1671–1674PubMedCrossRef

13.

Maeda S, Shibata J, Fujiyama S et al (2003) Long-term follow-up of hepatic artrial chemoembolization with cisplatin suspended in lodized oil for hepatocellular carcinoma. Hepato-Gastroenterology 50:809–813PubMed

14.

Ueno K, Miyazono N, Inoue H et al (2000) Transcatheter arterial chemoembolization therapy using lodized oil for patients with unresectable hepatocellular carcinoma. Cancer 88:1574–1581PubMedCrossRef

15.

Inose H (2004) Through a fusion of intellectual assets from within and beyond the company, and through accelerated product development, we are aiming for growth in the health care field, and particularly growth in cancer-related treatment areas. Annual Report 10-13. Available at: http://www.nipponkayaku.co.jp/english/ir/report/pdf/2004/04e10-13.pdf

16.

Burton MA, Kelleher DK, Codde JP et al (1991) Changes in hepatic blood flow during regional hyperthermia. Int J Hyperthermia 7:271–277PubMedCrossRef

17.

Sakaguchi H, Yoshimura H, Nishimura Y et al (1990) Behavior of Anti-cancer drug of transcatheter hepatic segmental arterial chemoembolization using lipodol mixed with an anti-cancer drug followed by gelatine sponge assessed by Tc-99m perthechnetate. Jpn J Cancer Chemother 17:1725–1730

18.

Raoul JL, Heresbach D, Bretagne JF et al (1992) Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 70:585–590PubMedCrossRef

19.

Garnick MB, Ensminger WD, Israel M (1979) A clinical-pharmacological evalusion of hepatic arterial infusion of adriamycin. Cancer Res 39:4105–4110PubMed

20.

Campbell TN, Howell SB, Pfeifle CE et al (1983) Clinical pharmacokinetics of intraarterial cisplatin in humans. J Clin Oncol 12:755–762

21.

Harima K, Harima Y, Hasegawa T et al (1995) Transcatheter arterial emboliazion as a model of cisplatin-retention enhancement on the VX2 tumor uterus transplants. CardioVasc Interv Radiol 18:30–34CrossRef

Title: Transarterial Chemoembolization Using Cisplatin Powder in a Rabbit Model of Liver Cancer
Authors: Kengo Morimoto
Hiroshi Sakaguchi
Toshihiro Tanaka
Kiyosei Yamamoto
Hiroshi Anai
Takayuki Hayashi
Mitsuo Satake
Kimihiko Kichikawa
Publication date: 01-09-2008
Publisher: Springer-Verlag
Published in: CardioVascular and Interventional Radiology / Issue 5/2008
Print ISSN: 0174-1551
Electronic ISSN: 1432-086X
DOI: https://doi.org/10.1007/s00270-008-9367-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Transarterial Chemoembolization Using Cisplatin Powder in a Rabbit Model of Liver Cancer

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2008

Usefulness of the “Rendezvous” Technique in Living Related Right Liver Donors with Postoperative Biliary Leakage from Bile Duct Anastomosis

Palliation of Obstructing Malignant Colonic Lesions Using Self-Expanding Metal Stents: A Single-Center Experience

Percutaneous Management of Biliary Strictures After Pediatric Liver Transplantation

Early and Late Retrieval of the ALN Removable Vena Cava Filter: Results from a Multicenter Study

Percutaneous Vertebroplasty and Bone Cement Leakage: Clinical Experience with a New High-Viscosity Bone Cement and Delivery System for Vertebral Augmentation in Benign and Malignant Compression Fractures

Radiofrequency Ablation of Colorectal Liver Metastases: Small Size Favorably Predicts Technique Effectiveness and Survival